大多数经口机器人手术 (TORS) 手术后普遍存在疼痛，并且可能会限制吞咽功能。目前，关于 TORS 最佳疼痛治疗的知识有限。除了多模式基本镇痛方案外，该临床试验将患者随机接受高剂量地塞米松或低剂量地塞米松治疗。该试验的目的是使用视觉模拟量表 (VAS) 调查 TORS 舌扁桃体切除术后休息和吞咽时的疼痛强度。次要结局是可接受的食物浓度、恶心、呕吐、阿片类药物救援使用、住院时间、饲管放置、再入院、血糖水平和术后并发症。该试验于 2020 年 8 月至 2022 年 10 月期间进行。符合条件的患者是计划接受 TORS 的患者-L 治疗阻塞性睡眠呼吸暂停综合征或作为原发灶不明的头颈癌诊断检查的一部分。18 名患者按 1:1 进行随机分组。在休息或吞咽期间报告的 VAS 评分总体上各组之间没有显着差异 (p ≥ .05)。总体而言，次要结局没有差异。分配到基本多模式镇痛药包以及高剂量地塞米松或低剂量地塞米松治疗的两个治疗组的疼痛强度没有差异。该试验是第一个在手术相关活动中纳入疼痛测量的随机对照试验，从而为未来的康复研究创建了一个平台。

Pain is prevalent after most TransOral Robotic Surgery (TORS) procedures and may limit function i.e. swallowing. Currently, there is limited knowledge regarding optimal pain treatment in TORS.This clinical trial randomized patients to either a high-dose dexamethasone or low-dose dexamethasone treatment in addition to a multimodal basic analgesic protocol. The aim of the trial was to investigate the pain intensity during rest and swallowing using the Visual Analogue Scale (VAS) after TORS lingual tonsillectomy. Secondary outcomes were acceptable food consistency, nausea, vomiting, opioid rescue usage, length of hospitalization, feeding tube placements, readmissions, blood glucose levels and postoperative complications.The trial was conducted between August 2020 and October 2022. Eligible patients were patients scheduled for TORS-L treatment of obstructive sleep apnea syndrome or as part of the diagnostic work-up of head and neck carcinoma of unknown primary.Eighteen patients were and randomized 1:1. There were overall no significant differences between groups in the reported VAS scores during rest or swallowing (p ≥ .05). Overall, there were no differences in the secondary outcomes.There were no differences in the pain intensity in the two treatment groups allocated to a basic multimodal analgesic package and either high-dose dexamethasone or low-dose dexamethasone treatment. The trial is the first RCT to include pain measurement during a procedure-relevant activity, thus creating a platform for future recovery studies.